N. Haas, J. Magnolia, and R. Uzzo, Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial., Journal of Clinical Oncology, vol.33, issue.7_suppl, p.403, 2015.
DOI : 10.1200/jco.2015.33.7_suppl.403

A. Zisman, A. Pantuck, and F. Dorey, Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System, Journal of Clinical Oncology, vol.19, issue.6, pp.1649-57, 2001.
DOI : 10.1200/JCO.2001.19.6.1649

C. Allegra, G. Yothers, O. Connell, and M. , Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial, Journal of Clinical Oncology, vol.31, issue.3, pp.359-64, 2013.
DOI : 10.1200/JCO.2012.44.4711

A. De-gramont, E. Van-cutsem, and H. Schmoll, Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial, The Lancet Oncology, vol.13, issue.12, pp.1225-1258, 2012.
DOI : 10.1016/S1470-2045(12)70509-0

D. Cameron, J. Brown, and R. Dent, Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial, The Lancet Oncology, vol.14, issue.10, pp.933-975, 2013.
DOI : 10.1016/S1470-2045(13)70335-8